fda tirzepatide update today https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound FDA says the tirzepatide weight-loss

doi: 10.1016/j.autneu.2011.07.004 81 SnyderEMBeckKCDietzNMEisenachJHJoynerMJTurnerSTet al

Os agonistas dos recetores do GLP-1 funcionam imitando a ao desta hormona

The depletion of nuclear glutathione impairs cell proliferation in 3t3 fibroblasts

However, a 2025 meta-analysis published in the Journal of the American Heart Association found that people who had been taking GLP-1 medications for 78 weeks or longer (roughly a year and a half) had a significantly higher risk of developing a DVT compared to non-users

Weekly injection scheduler (Ozempic/Wegovy) Pick one anchor: Sunday night after brushing teeth Monday morning after shower Friday after work (before weekend travel) Then add redundancy: Calendar event (recurring weekly) Phone alarm Keep supplies in one visible place Checkin points: Because Ozempic and Wegovy titrate in 4week steps on the FDA labels, set a recurring checkin every 4 weeks to review side effects and adherence (FDA Ozempic label, 2025